RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal
加拿大皇家银行将阿尔卑斯免疫科学的评级从跑赢大盘下调至板块，消除投机风险，在顶点交易中将目标股价从41美元上调至65美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册